Tag: nasdaq:aptx

November 12, 2019

Aptinyx Begins Two Phase 2 Studies of NYX-2925

The company is evaluating its NYX-2925 treatment in painful diabetic peripheral neuropathy and fibromyalgia.
August 21, 2019

Aptinyx Presents Data of NYX-458 in Preclinical Model of Head Injury

Aptinyx (NASDAQ:APTX) has announced presentation of preclinical data on its novel NMDA receptor modulator, NYX-458. As quoted in te press...
April 3, 2019

Aptinyx Releases Positive Data on Novel NMDA Receptor Modular Treating Parkinson’s Disease

Aptinyx (NASDAQ:APTX) has announced positive preclinical data on its novel NMDA receptor modulator, NYX-458, showing reverse effects in a non-human...
December 24, 2018

Pharma Outlook 2019: Drug Pricing Dialogue Continues

During this challenging time in healthcare news, our pharma outlook aims to help investors steer through the industry.
August 2, 2018

Aptinyx Initiates Phase 1 Study of NYX-458

Aptinyx (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced...